A publication in Molecular Cancer Therapeutics has shed new light on the mechanisms by which anti-HER2/3 combination therapies can cause diarrhea.
The REPROCELL Blog
REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.
ISSCR (the International Society for Stem Cell Research) is the preeminent stem cell research group in the world. ISSCR is holding its 2018 Annual Meeting in Melbourne, Australia – and REPROCELL will be there.
Join us 20-23 June at booth 74 and learn how we can help you with your stem cell needs.
REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.
The use of animals to predict the risk of adverse effects in humans is a long-standing debate within Pharma and also in society at large. Moreover, safety issues leading to clinical attrition remain a problem and a major financial drain on Pharma.
When you are considering beginning a project involving iPSC reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider.
REPROCELL Europe’s CEO, Dr David Bunton, was part of last week's trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP.
As part of our contract services at REPROCELL, we offer induced pluripotent stem cell (iPSC) characterization by immunocytochemistry (ICC). Planning ICC can be tricky, as it requires careful selection of compatible antibodies and fluorochromes. However, if successful, the results are fantastic! Don’t waste valuable research time performing ICC, and let our experts do the work for you!
Progressive and innovative Pharmaceutical and Biotechnology companies ask themselves several key questions when it comes to Drug Discovery and Development:
• How and where can we be research smarter?
• How can we reduce uncertainty?
• How can we better predict efficacy and safety?
• How can we reduce costs?
One route to making the drug discovery process smarter and more efficient is to use human tissue at one or more stages in the development process.
On Tuesday 20th March 2018 REPROCELL Europe Ltd’s CEO Dr David Bunton appeared in front of the Economy, Jobs and Fair Work Committee at the Scottish Parliament to discuss Scotland’s Economic performance. He was also joined by:
• Dr Diane Harbison, CEO, of Stratified Medicine Scotland
• Claire Mack, CEO, of Scottish Renewables
• Gareth Wynn, Stakeholder and Communications Director, Oil & Gas UK